Global InformationPenbraya information
Penbraya is a pentavalent conjugate vaccine developed by Pfizer for the prevention of invasive meningococcal disease in people 10 through 25 years of age.[1] Invasive meningococcal disease, caused by the bacterium Neisseria meningitidis, can lead to serious conditions such as meningitis (inflammation of the brain and spinal cord lining) and septicemia (bloodstream infection).[2] Penbraya is approved for use by the US Food and Drug Administration (FDA).[3] Penbraya is the first and only pentavalent vaccine that provides coverage against the five most common serogroups causing meningococcal disease in adolescents and young adults.[4]
- ^ "FDA Approves Pentavalent Meningococcal Vaccine from Pfizer for Ages 10 to 25 years". Patient Care Online. 24 October 2023. Retrieved 25 February 2024.
- ^ "Meningococcal Disease". U.S. Centers for Disease Control and Prevention (CDC). 1 September 2023. Retrieved 25 February 2024.
- ^ "Penbraya". U.S. Food and Drug Administration (FDA). 27 November 2023.
- ^ "Approval-first for meningococcal vaccine". European Pharmaceutical Review. Retrieved 26 February 2024.